It has been reported that the class IIa HDAC inhibitor TMP195 could alter the tumor microenvironment and reduce tumor burden and pulmonary metastases by modulating macrophage phenotype in a macrophage-dependent autochthonous mouse model of breast cancer. This evidence concerns the gene HDAC9 and neoplasm.